Sobi appoints Birgitte Volck as Chief Medical Officer

05-06-2012: Birgitte Volck has been appointed Senior Vice President, Chief Medical Officer at Sobi with responsibility for Clinical Development, Regulatory Affairs, Drug Safety and Medical Affairs.

Birgitte Volck is currently Executive Development Director, Bone, Neuroscience & Inflammation at Amgen Limited in Uxbridge, UK. She has held several senior positions within Amgen since 2007, including Executive Medical Director, Nordic & Baltic Region. Prior to Amgen she was Nordic Medical Director & Project Director at Genzyme A/S in Denmark 2004-2007, and Vice President, Clinical Development & Medical Affairs at Pharmexa A/S in Denmark 2001-2004.

During 1991-2000 she had various clinical and scientific assignments, mainly within rheumatology, at the Copenhagen University Hospitals. She holds a PhD and has published a number of scientific papers related to inflammation, connective tissue metabolism, biomarkers and arthritis.

Birgitte Volck, 49 years, is MD and PhD from the University of Copenhagen. She will report to CEO Geoffrey McDonough and will be a member of the Executive Leadership Team. She will assume her position on August 1, 2012.